N-Methyl-N-2-propynyl-1-indanamine hydrochloride, (S)- | 136314-73-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-Methyl-N-2-propynyl-1-indanamine hydrochloride, (S)-
• 英文别名: (1S)-N-methyl-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine;hydrochloride
• CAS: 136314-73-3
• 化学式: C13H16ClN
• 分子量: 221.72
• InChiKey: DWMQCWYIMZWFPL-ZOWNYOTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.66
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it
  申请人：Teva Pharmaceutical Industries Limited

  公开号：EP0436492A2

  公开（公告）日：1991-07-10

  R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.

  R(+)-N-丙炔基-1-氨基茚烷，其制备、使用和含有该化合物的制药组合物。这种新型化合物被发现可用于治疗帕金森病、记忆障碍、阿尔茨海默病（DAT）、抑郁症和多动症等人类病患。
• Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
  申请人：Youdim B.H. Moussa

  公开号：US20070100001A1

  公开（公告）日：2007-05-03

  The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.

  该发明提供了使用R(+)-N-丙炔基-1-氨基茚的甲磺酸盐治疗帕金森病、记忆障碍、抑郁症、多动症、注意力缺陷障碍、痴呆症、脑缺血、中风、头部创伤、脊髓创伤、神经创伤、神经退行性疾病、神经毒性损伤、多发性硬化症、神经损伤、情感疾病、精神分裂症或从成瘾物质中戒断症状的方法。
• Use of r-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
  申请人：Teva Pharmaceutical Industries, Ltd.

  公开号：US20030065038A1

  公开（公告）日：2003-04-03

  The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargy-1-aminoindan, or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan

  本发明提供了R（+）-N-丙炔基-1-氨基茚和其药学上可接受的盐，以及含有它们的药物组合物。本发明还提供了使用R（+）-N-丙炔基-1-氨基茚或本发明中药学上可接受的盐治疗帕金森病、记忆障碍、痴呆症、抑郁症、多动症、情感疾病、神经退行性疾病、神经毒性损伤、中风、脑缺血、头部创伤、脊髓创伤、神经创伤、精神分裂症、注意力缺陷障碍、多发性硬化症或戒断症状的方法。本发明还提供了一种预防主体神经损伤的方法。最后，本发明提供了制备R（+）-N-丙炔基-1-氨基茚、其盐和外消旋N-丙炔基-1-氨基茚的方法。
• R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN FOR THE TREATMENT OF VARIOUS DISEASES AND MESYLATE, ESYLATE AND SULFATE THEREOF
  申请人：TEVA PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0812190B1

  公开（公告）日：2004-12-08
• USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF
  申请人：Teva Pharmaceutical Industries, Inc.

  公开号：EP0828485A1

  公开（公告）日：1998-03-18